Pyridazine compounds and methods

Details Pyridazine compounds and methods Pyridazine compounds and methods

2008-05-12

2011-11-22

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S234000

Reexamination Certificate

active

08063047

ABSTRACT:
The invention relates to novel chemical compounds of Formula Icompositions and methods of using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

REFERENCES:
patent: 2857384 (1958-10-01), Druey, J. et al.
patent: 3464988 (1969-09-01), Holava, Jr. et al.
patent: 4169158 (1979-09-01), Laborit
patent: 4508720 (1985-04-01), Kan et al.
patent: 4562196 (1985-12-01), Horn et al.
patent: 4631286 (1986-12-01), Shutske et al.
patent: 4654343 (1987-03-01), Albright et al.
patent: 4710499 (1987-12-01), Wermuth et al.
patent: 4721711 (1988-01-01), Chambon et al.
patent: 4754050 (1988-06-01), Shutske et al.
patent: 4755511 (1988-07-01), Warrington
patent: 4816456 (1989-03-01), Summers
patent: 4835275 (1989-05-01), Shutske et al.
patent: 4839364 (1989-06-01), Shutske et al.
patent: 4895841 (1990-01-01), Sugimoto et al.
patent: 4948807 (1990-08-01), Rosin et al.
patent: 4977152 (1990-12-01), Biziere et al.
patent: 5045541 (1991-09-01), Nakao et al.
patent: 5100901 (1992-03-01), Sugimoto et al.
patent: 5104880 (1992-04-01), Kozikowski
patent: 5484490 (1996-01-01), Tokita et al.
patent: 5554780 (1996-09-01), Wolf
patent: 5693668 (1997-12-01), Schirlin et al.
patent: 5760267 (1998-06-01), Gandolfi et al.
patent: 5929084 (1999-07-01), Zhu et al.
patent: 6194403 (2001-02-01), Hu et al.
patent: 2003/0176437 (2003-09-01), Watterson et al.
patent: 2005/0137397 (2005-06-01), Nelson
patent: 2005/0143381 (2005-06-01), Yu et al.
patent: 2005/0192278 (2005-09-01), Ewing et al.
patent: 2006/0073472 (2006-04-01), Watterson et al.
patent: 2008/0021035 (2008-01-01), Watterson et al.
patent: 2008/0318899 (2008-12-01), Watterson et al.
patent: 2009/0029985 (2009-01-01), Watterson et al.
patent: 0072726 (1983-02-01), None
patent: 0 094 038 (1983-11-01), None
patent: 0 211 437 (1987-02-01), None
patent: 0211457 (1987-02-01), None
patent: 0382634 (1990-08-01), None
patent: 0628550 (1994-12-01), None
patent: 1061077 (2000-12-01), None
patent: 2141697 (1973-01-01), None
patent: 2 847 253 (2004-05-01), None
patent: 63295577 (1988-12-01), None
patent: 04021670 (1992-01-01), None
patent: 04187674 (1992-07-01), None
patent: WO-98 39000 (1998-09-01), None
patent: WO9839000 (1998-09-01), None
patent: 9846574 (1998-10-01), None
patent: 0142241 (2001-06-01), None
patent: WO-02 22605 (2002-03-01), None
patent: 03018563 (2003-03-01), None
patent: PCTEP2003047577 (2003-06-01), None
patent: 2004046117 (2004-06-01), None
patent: WO2004052348 (2004-06-01), None
patent: 2004062652 (2004-07-01), None
patent: 2004100958 (2004-11-01), None
patent: 2004101538 (2004-11-01), None
patent: 2005009976 (2005-02-01), None
patent: 2005030731 (2005-04-01), None
patent: 2005061509 (2005-07-01), None
patent: 2005063761 (2005-07-01), None
patent: WO-2006-026135 (2006-03-01), None
patent: 2006050359 (2006-05-01), None
patent: 2006050389 (2006-05-01), None
patent: WO-2006 050389 (2006-05-01), None
patent: 2007127375 (2007-04-01), None
patent: 2007127475 (2007-04-01), None
patent: 2007130383 (2007-04-01), None
patent: WO-2007 127375 (2007-04-01), None
patent: 2007127448 (2007-11-01), None
patent: 2007127474 (2007-11-01), None
patent: WO-2007-127488 (2007-11-01), None
patent: 2008109437 (2008-09-01), None
patent: WO-2008 109437 (2008-09-01), None
Griesser, in Chapter 8, The Importance of Solvates (pp. 211-230), in the text, Polymorphism: In the Pharmaceutical Industry, Hilfiker, 2006.
Wikipedia, Isomers, last modified Aug. 16, 2010, http://en.wikipedia.org/wiki/Isomer, downloaded Aug. 24, 2010.
Valentza, et al., Bioorg. & Med. Chem. Ltrs. (Oct. 3, 2003), 13(20), 3465-3470.
Suzuki, et al., Heterocycles (2002), 57(4), 723-731.
Costantino, et al., II Farmaco (2000), 55(8), 544-552.
Sotelo, et al., Synthetic Communications (2000), 30(1), 1-7.
Villa, et al., J. Het. Chem. (1999), 36(2), 485-492.
Costantino, et al., J. Med. Chem. (1996), 39(22), 4396-4405.
Cignarella, et al., J. Med. Chem. (1989), 32(10), 2277-82.
Garcia Mera, et al., Anales de Quimica, Serie C: Quimica Organica y Bioquimica (1985), 81(3), 280-3.
Bhattacherjee, et al., (1958) Zeitschrift fur Kristallographie, vol. 110, No. 1-6, pp. 472-474.
Bluhm, J. Het. Chem. (1981), 18, 189-90.
Partyka, et al., J. Med. Chem. (1971), 14(3), 262-4.
Allen, et al., J. Am. Chem. Soc. (1951), 73, 5850-6.
Borsche, et al., Justus Liebigs Annalen der Chemie (1943), 555, 70-7.
Hu, et al., “Amyloid-B peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release,” Brain Res. 785-195-206 (1998).
Hu, W., et al., “Pyridazines as a New Chemotype for Alzheimer's Disease Drug Discovery that Targets Disease Progression,” 29th National Medicinal Chemistry Symposium, University of Wisconsin—Madison, Jun. 27-Jul. 1, 2004, Abstract and Poster.
Jones, R.G., “Pyrazines and Related Compounds. I. A New Synthesis of Nydroxypyrazines,” J. Amer. Chem. Soc. 71: 78-81 (1949).
Karpus, W.J., et al., “Inhibition of experimental autoimmune encaphalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug,” J. Neuroimmunology 203(1): 73-78 (2008).
LaDu, et al., “Apolipoprotein E receptors Mediate the Effects of beta-Amyloid on Astrocyte Vultures,” J. Biol. Chem. 275:33974-33980 (2000).
LaDu, et al., “Apolipoprotein E and apolipoprotein E Receptors Modulate a beta-induced gilal neuroinflammatory responses,” Nuerochem Intl. 39:427-434 (2001).
Lam, et al., “Mechanism of glial activation by S100B: involvement of the transcription factor NFxB,” Nuerobiol. Aging 22:765-772 (2001).
Melikian, et al., “Condensation of Muscimol or Thiomuscimol with Aminopyridazines Yields GABA-A antagonists,” J. Med. Chem. 35, 4092-4097 (1992).
Merck: “The Merck Manual,” Merck & Co., U.S.A., p. 1398, col. 2, “prognosis and treatment of Alzheimer's disease,” (1999).
Mirzoeva, et al., “Screening in a cell-based assay for inhibitors of microglial nitric oxide production reveals calmodulin-regulated protein kinases as potential drug discovery targets,” Brain Res. 844:126-134 (1999).
Mirzoeva, et al., “Discovery of a 3-amino-6-phenyl-pyridazine Derivative as a New Synthetic Antineuroinflammatory Compound,” J. of Medicinal Chem. 45(3):563-566 (Watterson) (2002).
Munoz, L., et al., “A novel p38 alpha MAPK inhibitor suppresses btain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model,” J. Neuroinflammation 4:21 (Sep. 2007).
“Compound holds promise for neurodegenerative diseases,” Nelson Lancet Neurology 5(3) 210 (2006).
Hirohaski, et al., Pharmacological Studies with the Alpha2-Adrenoceptor Antagonist Midaglizole, Arzneim.-Forsch./Drug Res 41:9-18 (1991).
Pirvola, U., et al., “Rescue of Hearing, Auditory Hair Cells, and Neurons by CEP-1347/KT7515, an Inhibitor of c-Jun N-Terminal Kinase Activation,” J. Neuroscience, 20:43-50 (2000).
Prusiner, S.B., et al. “Shattuck Lecture—Neurodegenerative Diseases and Prions,” New Engl. J. Med. 344:1516-1526 (2001).
Ranaivo, H.R., et al., “Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration,” Jrnl. of Neurosc. 26(2) 662-670 (2006).
Ranaivo, H.R., et al., “Development of Orally Bioavailable Pyridazines that Suppress Neuroinflammation,” 9th International Symposium on the Chemistry and Pharmacology of Pyridazines, Antwerp, Belgium, Jul. 2004, Abstract & Power.
Saturnino,

Affiliated with

Also associated with

Rating

Pyridazine compounds and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyridazine compounds and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridazine compounds and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4299028